Get ready for a morning dose of financial insights and some juicy business stories! We're diving into the world of CNBC's Morning Squawk, where five key developments will keep investors on their toes.
The Richest Man's $1 Trillion Windfall
Elon Musk, the world's wealthiest individual, is about to add another zero to his net worth. Tesla shareholders have given the green light to Musk's nearly $1 trillion compensation plan, despite opposition from proxy advisors. This move grants Musk 12 tranches of shares if Tesla hits specific milestones over the next decade, and it also boosts his voting power, increasing his ownership stake significantly.
But here's where it gets controversial: one of those milestones involves delivering 1 million Optimus humanoid robots, which Musk claims will "eliminate poverty" and be "bigger than cell phones." However, these robots are not yet available, and Musk hasn't provided a timeline for their development, leaving some investors questioning the feasibility of this ambitious goal.
AI Stocks Under Pressure
The market is feeling the weight of concerns about AI stock valuations. Stocks resumed their downward trend yesterday as traders focused on the potential risks associated with highly valued AI stocks. Shares of Nvidia, Advanced Micro Devices, and Microsoft all closed lower, dragging the major averages into negative territory for the week.
The tech-heavy Nasdaq Composite dropped 1.9%, and the Dow Jones Industrial Average lost a substantial 400 points. Additionally, a murky employment picture, with layoffs surging in October, has added to the market's woes. With the government shutdown preventing the release of the nonfarm payrolls report, investors are left to speculate on the state of the job market.
A Price Cut for Obesity Drugs
President Donald Trump has announced deals with Eli Lilly and Novo Nordisk to drastically reduce the prices of their obesity drugs. This move not only benefits patients but also marks a significant development, as Medicare will cover GLP-1 drugs for obesity starting mid-2026. The monthly out-of-pocket costs for these popular drugs could range from $50 to $350, depending on dosage and insurance coverage, making them more accessible to those in need.
AI Bailouts: A Heated Debate
The topic of AI bailouts has sparked a heated discussion. David Sacks, Trump's AI and crypto advisor, has stated that there will be "no federal bailout for AI." This comment comes in response to OpenAI CFO Sarah Friar's earlier statement about seeking a government "backstop" or "guarantee" to fund their investments. However, Friar later clarified her position, emphasizing the importance of both the private sector and government in building technological strength.
Meanwhile, OpenAI CEO Sam Altman predicts the AI startup will generate over $20 billion in annualized revenue this year and grow exponentially by 2030. The company has secured infrastructure deals worth over $1.4 trillion, but investors are questioning the source of funding for these commitments.
Target's In-Store Woes and a New Strategy
Target, once a model for big-box retailers, is facing customer complaints about messy aisles, long lines, and locked-up products. In response, the company is shaking up its website strategy. Unlike its competitors, Target uses its stores as fulfillment centers for e-commerce orders. However, under its new approach, Target will limit which stores pick, pack, and ship online purchases, hoping to free up employees to enhance the in-store experience.
So, there you have it! A morning squawk full of financial insights and intriguing business developments. What do you think about these stories? Feel free to share your thoughts and opinions in the comments below!
